An efficient method to identify virus-specific TCRs for TCR-T cell immunotherapy against virus-associated malignancies.
Immunotherapy
TCR cloning
TCR transduced T cells
Virus-specific TCRs
Journal
BMC immunology
ISSN: 1471-2172
Titre abrégé: BMC Immunol
Pays: England
ID NLM: 100966980
Informations de publication
Date de publication:
28 09 2021
28 09 2021
Historique:
received:
24
05
2021
accepted:
14
09
2021
entrez:
29
9
2021
pubmed:
30
9
2021
medline:
29
1
2022
Statut:
epublish
Résumé
Adoptive transfer of T cells genetically engineered with a T cell receptor (TCR) is a promising cancer treatment modality that requires the identification of TCRs with good characteristics. Most T cell cloning methods involve a stringent singularization process, which necessitates either tedious hands-on operations or high cost. We present an efficient and nonstringent cloning approach based on existing techniques. We hypothesize that after elimination of most nonspecific T cells, a clonotype with high quality could outcompete other clonotypes and finally form a predominant population. This TCR identification method can be used to clone virus-specific TCRs efficiently from cancer patients and is easily adoptable by any laboratory.
Identifiants
pubmed: 34583647
doi: 10.1186/s12865-021-00455-3
pii: 10.1186/s12865-021-00455-3
pmc: PMC8480097
doi:
Substances chimiques
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
65Informations de copyright
© 2021. The Author(s).
Références
J Immunother. 2010 Nov-Dec;33(9):983-90
pubmed: 20948438
Clin Cancer Res. 2014 May 15;20(10):2684-94
pubmed: 24658154
J Clin Oncol. 2005 Apr 1;23(10):2346-57
pubmed: 15800326
Cell Res. 2017 Jan;27(1):59-73
pubmed: 28008927
J Immunother. 2005 Jan-Feb;28(1):53-62
pubmed: 15614045
Clin Vaccine Immunol. 2014 Feb;21(2):256-9
pubmed: 24351754
J Immunother. 2003 Jul-Aug;26(4):332-42
pubmed: 12843795
Nat Rev Cancer. 2002 Jan;2(1):59-65
pubmed: 11902586
Methods Mol Biol. 2009;514:65-93
pubmed: 19048214
J Immunother. 2008 Oct;31(8):742-51
pubmed: 18779745
Nat Biotechnol. 2014 Jul;32(7):684-92
pubmed: 24952902
J Clin Oncol. 2014 Mar 10;32(8):798-808
pubmed: 24344220
Blood. 2018 Nov 1;132(18):1911-1921
pubmed: 30150207
J Virol. 2004 Nov;78(21):11451-60
pubmed: 15479788
N Engl J Med. 1988 Dec 22;319(25):1676-80
pubmed: 3264384
Lab Chip. 2018 Dec 4;18(24):3733-3749
pubmed: 30397689
Nat Rev Cancer. 2008 Apr;8(4):299-308
pubmed: 18354418
PLoS One. 2013 Apr 26;8(4):e61384
pubmed: 23637823
Annu Rev Immunol. 2015;33:787-821
pubmed: 25706097
J Neurooncol. 2011 Jun;103(2):231-8
pubmed: 20820869
J Exp Med. 1979 Jan 1;149(1):273-8
pubmed: 310861
Biotechniques. 2001 Apr;30(4):892-7
pubmed: 11314272
Hum Gene Ther. 2009 Nov;20(11):1240-8
pubmed: 19702439
Clin Cancer Res. 2015 Oct 1;21(19):4431-9
pubmed: 26429982
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669936
Cancer Immunol Immunother. 2020 May;69(5):859-865
pubmed: 31915853
J Clin Oncol. 2015 May 10;33(14):1521-2
pubmed: 25847926
Mol Ther Methods Clin Dev. 2016 Jan 27;3:15054
pubmed: 26858965
Science. 1992 Jul 10;257(5067):238-41
pubmed: 1352912
Sci Transl Med. 2015 Aug 19;7(301):301ra131
pubmed: 26290413
N Engl J Med. 2008 Jul 31;359(5):539-41
pubmed: 18669440
J Clin Oncol. 2015 May 10;33(14):1543-50
pubmed: 25823737
J Immunother Cancer. 2019 Aug 28;7(1):229
pubmed: 31455429
J Immunol. 2008 Jun 1;180(11):7736-46
pubmed: 18490778
Nat Rev Immunol. 2002 Jul;2(7):512-9
pubmed: 12094225
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998
pubmed: 28446615
Trends Mol Med. 2010 Feb;16(2):77-87
pubmed: 20122868
J Immunol. 2007 Nov 1;179(9):5803-10
pubmed: 17947653